Every study, trial, video and milestone carries topic tags; these pages collect them.
What CETP does during bacterial infection, and whether inhibiting it helps. A secondary thread with more evidence behind it than most readers expect: Mendelian randomisation finds genetically proxied CETP inhibition protects against sepsis, anacetrapib improves survival in pneumococcal sepsis in mice, and endotoxin has been known since the 1990s to suppress CETP. Not all of it agrees, which is why the thread is worth reading whole.
Cohorts, biobanks and registries in which CETP is the exposure.
Where a class with no approval and no positive outcomes trial sits in lipid guidance.
What CETP inhibitors do to Lp(a), and where that fits. See also the sister site lp-a.org.
The exceptional-ageing literature and what it does and does not say about CETP.
CETP genotype, cognition and the questions obicetrapib inherited.
Blood pressure, aldosterone and the organ-system record the class must answer for.
Dose, exposure, interactions, and the tissue accumulation that ended one programme.
The transfer protein itself: structure, the hydrophobic tunnel, kinetics, what inhibition does.
Reverse cholesterol transport, efflux capacity and the hypothesis that started it all.
Why a class born to raise HDL is now developed on an LDL-lowering claim.
CETP variants, inherited deficiency and the Mendelian randomisation that reframed the class.
CETP inhibition as a strategy: rationale, comparisons and where it stands today.
The hard-endpoint record of the whole class, from ILLUMINATE to PREVAIL.
ILLUMINATE, the off-target pressor effect, and what the field learned from it.
Neutral in 2012, revived genotype-first, still being tested.
ACCELERATE and the end of the simple HDL hypothesis.
REVEAL, the only positive outcomes trial in the class, and the decision not to file.
The live agent: the phase 3 LDL-C programme, the CHMP opinion and the PREVAIL outcomes trial.
diabetes 130ancestry 101women 80statins 79liver 66inflammation 50assay 44plaque imaging 28obesity 27familial hypercholesterolaemia 24children 24kidney 22phase 3 21metabolic syndrome 19phase 2 16history 11cancer 11stroke 11ezetimibe 11pcsk9 9phase 1 7regulatory 6heart failure 2thrombosis 2aortic stenosis 1health economics 1